Cellular Proliferative Fraction of Metastatic Lymph Nodes Predicts Survival in Stage D1 (TxN+MO) Prostate Cancer
- 1 May 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 155 (5) , 1674-1677
- https://doi.org/10.1016/s0022-5347(01)66162-7
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki‐67 and PCNA expressionThe Prostate, 1995
- Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1‐2MO prostatic adenocarcinomaInternational Journal of Cancer, 1994
- Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators on Node-Negative Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 1993
- Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic CarcinomaBritish Journal of Urology, 1993
- Cell Proliferation in Prostatic Adenocarcinoma: In Vitro Measurement by 5-Bromodeoxyuridine Incorporation and Proliferating Cell Nuclear Antigen ExpressionJournal of Urology, 1993
- Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sectionsThe Journal of Pathology, 1992
- Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parametersThe Prostate, 1992
- Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinomaThe Prostate, 1992
- Monoclonal Antibody KI-67 Defined Growth Fraction in Benign Prostatic Hyperplasia and Prostatic CancerJournal of Urology, 1989
- The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostateCancer, 1987